Cibinetide (ARA-290)
ARA-290 / Cibinetide
- Peptide length
- 11 amino acids
Nonerythropoietic peptide analog
Open the sources to check how the studies were done and what they can support.
An erythropoietin-derived peptide studied in small human trials, including sarcoidosis-associated small-fiber neuropathy.
- Family
- Erythropoietin-derived analog
- Research target
- Proposed innate repair receptor
- Molecular form
- Nonerythropoietic peptide analog
What to know about the research
The cited trial found changes in nerve-fiber measures; the reported pain comparison did not reach conventional statistical significance. A surrogate change is not the same as proven symptom benefit.
Check the exact compound
Distinguish cibinetide from erythropoietin. Regulatory designations, if present, are not marketing approvals.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries